Our Pointillist Platform
Oncology drug discovery is currently limited by target herding, the clustering of too many companies developing too many programs against the same targets. Additionally, conventional drug targets lack epitope-level resolution resulting in therapies that are less selective and bind to healthy and tumor cells.
We are leveraging our revolutionary Pointillist Platform tumor-specific cell surface epitopes that enable the development of groundbreaking oncology therapies that target tumor cells only, resulting in increased potency and reduced toxicity.
We target tumor-specific cell surface epitopes
Scientists have discovered that in certain circumstances the same DNA can lead to differential cell surface protein presentation on tumor vs. normal cells. When this occurs unique tumor-specific cell surface epitopes can be exposed. Stipple Bio’s Pointillist Platform identifies these tumor-specific epitopes and also creates antibody binders that specifically bind to the tumor epitope allowing the development of precision cancer therapeutics with increased potency and reduced on-target/off-tumor toxicity.
